CASTLE BIOSCIENCES, INC. Castle Biosciences, Inc. Share Price
Equities
CSTL
US14843C1053
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.34 USD | +4.25% |
|
+5.33% | -5.75% |
| Sales 2024 * | 238M 19.02B | Sales 2025 * | 257M 20.6B | Capitalization | 561M 44.92B |
|---|---|---|---|---|---|
| Net income 2024 * | -61M -4.88B | Net income 2025 * | -55M -4.4B | EV / Sales 2024 * | 1.48 x |
| Net cash position 2024 * | 210M 16.78B | Net cash position 2025 * | 184M 14.76B | EV / Sales 2025 * | 1.46 x |
| P/E ratio 2024 * |
-9.08
x | P/E ratio 2025 * |
-10.4
x | Employees | 610 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Castle Biosciences, Inc.
More recommendations
More press releases
| 1 day | +4.25% | ||
| 1 week | +5.33% | ||
| Current month | -8.17% | ||
| 1 month | -5.79% | ||
| 3 months | -6.40% | ||
| 6 months | +55.50% | ||
| Current year | -5.75% |
1 week
18.76
20.77
1 month
18.5022.67
Current year
17.4225.60
1 year
9.2626.70
3 years
9.2678.92
5 years
9.26107.69
10 years
9.26107.69
| Managers | Title | Age | Since |
|---|---|---|---|
Derek Maetzold
FOU | Founder | 62 | 31/08/07 |
Franklin Stokes
DFI | Director of Finance/CFO | 54 | 30/11/17 |
Johnson Clare
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Derek Maetzold
FOU | Founder | 62 | 31/08/07 |
Daniel Bradbury
CHM | Chairman | 62 | 31/08/12 |
G. Cole
BRD | Director/Board Member | 68 | 05/12/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.99% | 11 M€ | -6.03% | - | |
| 0.60% | 12 M€ | -.--% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.02% | 237 M€ | +2.89% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 20.34 | +4.25% | 112,239 |
| 25/04/24 | 19.51 | -1.76% | 187,856 |
| 24/04/24 | 19.86 | -1.00% | 113,413 |
| 23/04/24 | 20.06 | +2.29% | 198,460 |
| 22/04/24 | 19.61 | +1.55% | 94,950 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
Calendar
02/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
20.34
USD
Average target price
33.11
USD
Spread / Average Target
+62.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.75% | 561M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- CSTL Stock
